Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-08-28 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年第三次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2025 third extraordinary shareholders meeting of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on a specific proposal regarding the 2025 semi-annual equity distribution plan, and legal opinions confirming the validity of the meeting and voting process. There is no financial data or detailed report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes rather than a full report or presentation.
2025-08-28 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司2025年半年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2025 Half-Year Continuous Supervision Tracking Report' issued by a sponsoring institution (中信证券股份有限公司) for a listed company (山西锦波生物医药股份有限公司). It details the ongoing supervision activities, including review of governance, financial controls, information disclosure, and compliance with regulatory requirements during the half-year period of 2025. The content includes detailed descriptions of supervisory tasks, findings, and compliance status, indicating it is a formal report on regulatory supervision rather than a financial report or announcement. The document length is over 5,000 characters and contains substantive content, not merely an announcement or certification. This type of document aligns with the category of Audit Report / Information (AR), as it is a standalone supervisory and audit-related report issued by the sponsor, focusing on compliance and internal controls rather than full financial statements or annual reporting. Therefore, the correct classification is AR with high confidence. H1 2025
2025-08-26 Chinese
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding the lifting of stock sale restrictions (解除限售公告) for certain shares held by former directors and supervisors. It details the number of shares being unlocked, the shareholders involved, and the updated share capital structure. There is no financial data, earnings information, or management discussion. The document is an official notice about changes in share restrictions and share availability for trading, which fits the category of Share Issue/Capital Change announcements. The document length is short (1584 characters), and it is not a report but an announcement of a capital-related event.
2025-08-25 Chinese
第四届监事会第九次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the ninth meeting of the fourth Supervisory Board of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details meeting logistics, attendance, and voting results on several proposals, including the cancellation of the Supervisory Board and amendments to the company charter. The document is an official announcement of board/management decisions rather than a full report or financial statement. It does not contain financial data or detailed management analysis but focuses on governance and board-level decisions. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short (1642 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2025-08-20 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It details the company's internal governance rules and procedures regarding related party transactions, including definitions, decision-making processes, disclosure requirements, and principles to ensure fairness and compliance with laws and regulations. It includes references to the company's board and shareholder meetings approving these internal rules. There are no financial statements, audit opinions, earnings data, or investor presentations. The document is a governance policy or internal management system rather than a financial report or announcement of voting results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (6187 characters) supports it being a full policy document rather than a brief announcement.
2025-08-20 Chinese
内部审计制度
Audit Report / Information Classification · 95% confidence The document is titled "内部审计制度" (Internal Audit System) and details the internal audit policies, organizational structure, responsibilities, authority, implementation, rewards and punishments, information disclosure, and archival management of the company. It includes references to the audit committee, internal control evaluation, and compliance with laws and regulations. The document is a formal announcement of the company's internal audit system approved by the board of directors on August 21, 2025. It is not a standalone audit report, nor is it an annual or interim financial report. It is also not a certification or a brief announcement but a detailed policy document. This fits best under the category of Audit Report / Information (AR), which includes applied accounting principles and internal audit information, excluding full annual reports. The document is 7795 characters long, which is substantive and detailed, not a mere announcement or certification. Therefore, the classification is AR with high confidence. Q3 2025
2025-08-20 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.